Survey: 66% of Californians oppose drug price transparency bill

Two-thirds of Californians do not support a drug price transparency bill before the California State Assembly, according to a recent survey commissioned by the Association for Accessible Medicines.

The legislation would require drugmakers to give the state a 60-day notice before raising the price of a drug more than 10 percent, among other regulations for branded drugmakers. The bill's opponents argue the regulations will place a burden on generic competition and cause the price of generic drugs to increase.

Market Probe, which conducted the survey on behalf of AAM, polled more than 1,000 California residents about the drug price bill earlier this month. Sixty-six percent of respondents were unwilling to support the bill, saying it will harm patients who rely on cheaper generic drugs.

"Despite the perception that consumers support this legislation, voters are rightfully concerned about how it will impact their healthcare — and their wallet," said Carrie Hartgen, AAM's vice president of state government affairs, in an emailed release. "Any new requirements must protect the ability of generics to effectively compete in the marketplace and continue to drive down health care costs in California."

More articles on supply chain:

Samsung widens stake in prescription drug market through partnership with Japanese pharmaceutical company
Patients brace for price of 'breakthrough' leukemia drug CTL019
Bella Pharmaceuticals voluntarily recalls all lots of unexpired sterile drug products

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars